19-Feb-2026
No headlines found.
SAB BIO to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 4-Feb 9:00 AM ET)
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
Globe Newswire (Wed, 7-Jan 8:00 AM ET)
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Tue, 6-Jan 8:00 AM ET)
Globe Newswire (Thu, 18-Dec 8:00 AM ET)
Globe Newswire (Wed, 17-Dec 8:00 AM ET)
Globe Newswire (Mon, 8-Dec 8:00 AM ET)
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Sab Biotherapeutics trades on the NASDAQ stock market under the symbol SABS.
As of February 19, 2026, SABS stock price climbed to $3.79 with 192,597 million shares trading.
SABS has a beta of 1.48, meaning it tends to be more sensitive to market movements. SABS has a correlation of 0.10 to the broad based SPY ETF.
SABS has a market cap of $180.43 million. This is considered a Micro Cap stock.
Last quarter Sab Biotherapeutics reported $0 in Revenue and -$.21 earnings per share. This fell short of revenue expectation by $-249,998 and exceeded earnings estimates by $.30.
In the last 3 years, SABS traded as high as $14.50 and as low as $1.00.
The top ETF exchange traded funds that SABS belongs to (by Net Assets): VTI, VXF, AVSC.
SABS has outperformed the market in the last year with a return of +97.4%, while the SPY ETF gained +13.1%. However, in the most recent history, SABS shares have underperformed the stock market with its stock returning -3.1% in the last 3 month period and -10.4% for the last 2 week period, while SPY has returned +4.0% and -0.2%, respectively.
SABS support price is $3.54 and resistance is $3.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SABS shares will trade within this expected range on the day.